Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 12/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 12/20 | 0.39 |
| ▸ | WNT1 | P04628 | 11/20 | 0.39 |
| ▸ | ABL1 | P00519 | 4/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22797252 | 0.88 | WNT1 (0.48) | GSK3BDYRK1AWNT1ABL1 | |
| SCHEMBL22609238 | 0.83 | ACHE (0.33) | — | |
| SCHEMBL20919947 | 0.83 | CTSC (0.32) | ABL1MAP4K1 | |
| SCHEMBL20641848 | 0.81 | MAP4K1 (0.37) | MAP4K1 | |
| SCHEMBL20937485 | 0.77 | CHRNB2 (0.36) | GSK3BDYRK1AWNT1ABL1MAP4K1 | |
| SCHEMBL22797251 | 0.77 | PTPN2 (0.52) | ABL1 | |
| Hydrochloric Acid SCHEMBL23523227 | 0.76 | CHRNB2 (0.36) | GSK3BDYRK1AWNT1ABL1MAP4K1 | |
| SCHEMBL22609246 | 0.75 | WNT1 (0.37) | GSK3BDYRK1AWNT1 | |
| SCHEMBL20936735 | 0.74 | PTPN2 (0.39) | GSK3BDYRK1AWNT1ABL1 | |
| SCHEMBL23523709 | 0.73 | CHRM4 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325896-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2022-05-10 | — | — | US | disclosed |
| US-20200392117-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2020-12-17 | — | — | US | disclosed |
| EP-3732163-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2020-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392117-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM2, CHRM3, CHRM4 | GSK3B 4245/4885DYRK1A 2753/4885WNT1 4356/4885 |
| US-11325896-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | CHRM2, CHRM3, CHRM5 | GSK3B 4258/4885DYRK1A 3068/4885WNT1 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.